Vascular endothelial growth factor C (VEGF-C) is a critical activator of tumor lymphangiogenesis that recently has been strongly implicated in the tumor metastasis process. In this study, we identified that HRG-␤1 stimulated up-regulation of VEGF-C mRNA and protein of human breast cancer cells in a dosage-and time-dependent manner and that this up-regulation was de novo RNA synthesis-dependent. The HRG-␤1-induced increase in VEGF-C expression was effectively reduced by treatment with Herceptin, an antibody specifically against HER2. Also, when HER2 was overexpressed in MCF-7 cells that resulted in an evident increase in the VEGF-C level, suggesting an essential role of HER2 in mediating VEGF-C up-regulation by HRG-␤1. NF-B has been shown to be probably involved in interleukin-1␤-or tumor necrosis factor-␣-induced VEGF-C mRNA expression in human fibroblasts. Here we found that HRG-␤1 could stimulate NF-B nuclear translocation and DNA-binding activity via the IB␣ phosphorylationdegradation mechanism. Blockage of the NF-B activation cascade caused a complete inhibition of the HRG-␤1-induced elevation of VEGF-C. In promoter-reporter assay, the luciferase activities of the reporter constructs, including the putative NF-B site deleted and mutated form were significantly reduced after HRG-␤1 treatment as compared with the 1.5-kb VEGF-C promoter. Although investigating the upstream kinase pathway(s) involved in HRG-␤1-elicited NF-B activation and VEGF-C up-regulation, we found that HRG-␤1 could activate extracellular signal-regulated protein kinase 1/2, phosphatidylinositol 3-kinase, and p38 mitogen-activated protein kinase (MAPK) in MCF-7. However, only SB203580 (a specific inhibitor of p38 MAPK), not PD98059 nor LY294002, blocked the up-regulation of VEGF-C by HRG-␤1. A similar inhibition in VEGF-C expression was obtained by cell transfection with dominant-negative p38 (p38AF). Interestingly, the HRG-␤1-induced NF-B activation cascade was also effectively blocked by SB203580 treatment or p38AF transfection. Our data thus suggests that HRG-␤1 stimulated a NF-Bdependent up-regulation of VEGF-C through the p38 MAPK signaling pathway in human breast cancer cells.
Tumor progression and metastasis rely mainly on both vascular and lymphatic systems by which cancer cells can spread widely into regional or distant tissues. The high tumor metastasis is strongly associated with short disease-free survival periods and poor prognosis in cancer patients. In the past decades, many subsets of molecules have been reported to be critically involved in regulating the blood microvessel formation in tumor development (1) (2) (3) . Little is known about how cancer cells can migrate to regional lymph nodes or promote the proliferation of lymphatic vessel. Recent evidence showed that VEGF 1 -C and VEGF-D, two members of the VEGF family, are the ligands for VEGF receptor(R)-3, which can stimulate the lymphatic vessel growth (lymphangiogenesis) and also enhance lymphatic metastasis in animal model (4 -8) .
VEGF-C displays a high degree of similarity to VEGF-A, including conservation of the eight cysteine residues involved in intra-and intermolecular disulfide binding. The cysteinerich COOH-terminal region increases the half-life of the VEGF-C protein relative to the other members of the family (9, 10) . VEGF-C mRNA is first translated into a 58-kDa precursor from which the 29/31-kDa mature ligand is formed by a general proteolytic process independent of the cell type (11, 12) . The secreted 29/31-kDa VEGF-C polypeptide specifically binds to the VEGF receptor(R)-3, which is predominantly expressed on lymphatic endothelium in adults, and triggers survival and proliferative activity in the lymphatic endothelium via p42/p44 MAPK and phosphatidylinositol 3Ј-kinase (PI3K)/Akt signaling pathways (13) (14) (15) (16) . Supportively, VEGF-C expression has been detected in most of the important human cancers analyzed (17) , and its expression level correlated with lymph node metastases in especially thyroid, gastric, colorectal, lung, prostatic, and breast cancers (18 -23) . Clinical and experimental findings strongly suggest a potential role for VEGF-C-mediated lymphangiogenesis in human cancer metastasis. However, little is known about the regulation of VEGF-C in tumor cells to date.
HRG-␤1, a member of the epidermal growth factor-like growth factor family, is secreted from mesenchymal cells and acts as a combinatorial ligand for the HER3 and HER4 receptors in breast cancer cells (24 -26) . The binding of HRG-␤1 to its receptors activates a diversified signaling pathway by which many biological functions, including proliferation (27, 28) , differentiation (27, 29) , apoptosis (30, 31) , and migration (32, 33) , occur. These biological alterations induced by HRG-␤1 result in the invasive and metastasis-related properties in human breast cancer (25, 34, 35) . HRG-␤1 has been shown to participate in the regulation of many important gene expressions such as, metalloproteinases (36) , urokinase plasminogen activator (37) , paxillin (38, 39) , and VEGF-A (40) . The signaling pathways including PI3K, ERK1/2, and p38 MAPK have been shown to be responsible for those gene expressions in a complicated manner (36, 39) . However, these identified genes seem not to fully account for the role of HRG-␤1 in the progression of breast cancer. It is important to identify new downstream effector gene(s) in breast cancer cells in response to HRG-␤1.
This study was undertaken to investigate whether HRG-␤1 would regulate the expression of VEGF-C in human breast cancer cells. Here we demonstrate that HRG-␤1, but not other growth factors, is a potent agent to induce VEGF-C up-regulation. Using NF-B decoy or transfection with dominant-negative (DN)-IB␣ to specifically abrogate the HRG-␤1-mediated NF-B activation including nuclear translocation and DNAbinding activity that resulted in an inhibition of VEGF-C upregulation. Searching the upstream kinase regulator of NF-B signaling, we found that SB203580, a p38 MAPK inhibitor, but not PD98059 or LY294002, strongly abolished HRG-␤1-stimulated NF-B activation as well as the subsequent VEGF-C up-regulation. A similar result was obtained using transfection with DN-p38 (p38AF). Our current data demonstrates for the first time that HRG-␤1 potently up-regulates the VEGF-C gene through the activation of the p38 MAPK/NF-B signaling pathway.
EXPERIMENTAL PROCEDURES
Cell Cultures-Human breast cancer cell lines (MCF-7, SKBr3, and T47D), MCF-7 HER2/neu stable cell line expressing Her-2/neu (a kind gift from Dr. Ruey-Long Hung, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan), and HBL-100 immortalized human breast cell line were maintained in Dulbecco's modified Eagle's medium supplemented 10% fetal bovine serum with 2 mM L-glutamine (Invitrogen), 100 g/ml streptomycin, and 100 units/ml penicillin in a humidified 5% CO 2 atmosphere.
Transient Cell Transfections-p38AF dominant-negative mutant (generously provided by Dr. Ching-Chow Chen, Department of Pharmacology, College of Medicine, National Taiwan University, Taipei, Taiwan), dominant-negative 32/36A mutated form of IB␣ (kindly provided by Dr. Shuang-En Chuang), and vector were transfected into MCF-7 cells using transfection reagent FuGENE-6 (from Roche Molecular Biochemicals) per manufacturer's protocol. Twenty-four hours after transfection, cells were serum-starved for a further 24 h and stimulated with HRG-␤1, and then cells were lysed for analysis. Each experiment was repeated with three independent transfections, and transfection efficiency varied between 20 and 30%.
Reagents-Recombinant human heregulin-␤1, human interleukin-1␤, human interleukin-6, human interleukin-8, human tumor necrosis factor-␣, and human polyclonal VEGF-C antibody were purchased from R&D Systems (Minneapolis, MN). The kinase inhibitors LY294002, PD098059, and SB203580 were obtained from Sigma. The epidermal growth factor receptor inhibitor PD153035 and PMA (phorbol-12-myristate-13-acetate) were purchased from Calbiochem. Antibodies to human Her-2/neu, phospho-p38, p38, phospho-ERK1/2, ERK1/2, NF-B (p65), NF-B (p50), proliferating cell nuclear antigen, ␣-tubulin, and secondary horseradish peroxidase-conjugated antibodies were obtained from Santa Cruz Biotechnology. Antibodies to phospho-AKT and AKT were purchased from the Upstate Biotechnology. [␣-32 P]dCTP was obtained from Amersham Biosciences. Anti-Her-2 monoclonal antibody, Herceptin ® (Trastuzumab), was provided by Dr. Chih-Hsin Yang (Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan).
RNA Isolation and Reverse Transcriptase-Polymerase Chain Reaction-A total of 8 breast carcinoma patients' tissue RNA were obtained from the Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan. Total RNA was isolated using RNA-Bee TM reagent (Tel-Test, Inc.) as recommended by the manufacturer's instructions. Total RNA (1 g) was reverse-transcribed into single-stranded cDNA with Moloney murine leukemia virus Reverse Transcriptase and random hexamers (Promega, Madison, WI). Amplification of growth factor cDNAs and ␤-actin cDNA as an internal control in each reaction was carried out by polymerase chain reaction with the primers as described as follows. VEGF-C cDNA PCR are 5Ј-CAGTTACGGTCTGTGTCCAGT-GTAG-3Ј (forward) and 5Ј-GGACACACATGGAGGTTTAAAGAAG-3Ј (reverse). The primer sequences for VEGF-D cDNA PCR are 5Ј-TGGGT-CATCTTCTCGCGGTT-3Ј (forward) and 5Ј-GATGATGATATCGC-CGCGCT-3Ј (reverse). The primer sequences were as follows: VEGF-A cDNA PCR are 5Ј-AGCTACTGCCATCCAATCGC-3Ј (forward) and 5Ј-GGGCGAATCCAATTCCAAGAG-3Ј (reverse). Primers designed to amplify a fragment of HRG cDNA (corresponding to position in HRG-␤1 mRNA, GenBank TM M94166), spanning the variable EGF-like domain (forward primer: 5Ј-GTGTGAATGGAGGGGAGTGC-3Ј, reverse primer: 5Ј-CTTGGCGTGTGGAAATCTAC-3Ј). Primer sequences for HER2 cDNA PCR are 5Ј-AGGGAAACCTGGAACTCACC-3Ј (forward) and 5Ј-TGGATCAAGACCCCTCCTT-3Ј (reverse). PCR was carried out using specific primers for ␤-actin and GAPDH (␤-actin: forward, 5Ј-GATGAT-GATATCGCCGCGCT-3Ј, reverse, 5Ј-TGGGTCATCTTCTCGCGGTT-3Ј; GAPDH: forward, 5Ј-CCACCCATGGCAAATTCCATGGCA-3Ј, reverse, 5Ј-TCTAGACGGCAGGTCAGGTCCACC-3Ј). Primers were used at a final concentration of 0.5 M. Reaction mixture was first denatured at 95°C for 10 min. The PCR condition was 95°C for 1 min, 55°C for 1 min, and 72°C for 1 min, for 30 cycles, followed by 72°C for 10 min. Polymerase chain reaction products were visualized by ethidium bromide staining after agarose gel electrophoresis. Western Blot Analysis-Cells were starved in serum-free medium overnight then incubated with HRG-␤1 for different times or for various concentrations. Cells were washed two times with ice cold phosphatebuffered saline and lysed in buffer (50 mM Tris-HCl (pH 7.5), 120 mM NaCl, 0.5% Nonidet P-40, 100 mM NaF, 200 mM Na 3 VO 4 , 1 mM phenylmethylsulfonyl fluoride, 10 g/ml leupeptin, and 10 g/ml aprotinin) for 15 min on ice. The lysates were centrifuged in an Eppendorf at 4°C for 15 min. The equal amounts of protein from the cell lysates were resuspended in gel sample buffer, resolved by 10% SDS-polyacrylamide gel electrophoresis, and transferred to nitrocellulose membranes (Millipore). Membranes were blocked for 1 h in 5% (w/v) dry milk, phosphate-buffered saline, and 0.1% Tween 20. Primary antibodies as indicated were incubated with membranes for 2 h, and the membranes were washed in phosphate-buffered saline with 0.1% Tween 20. Subsequently, horseradish peroxidase-conjugated secondary antibodies were added for 1 h, and the membranes were washed in phosphate-buffered saline with 0.1% Tween 20. Renaissance ® (NEN Life Science Products) enhanced chemiluminescence reagent was used to detect membrane-bound protein by luminography. This light is captured on Kodak X-OMAT Blue Autoradiography film.
NF-B/Rel-specific Decoy Oligodeoxynucleotides-We used a phosphorothioate double-stranded decoy oligodeoxynucleotide carrying the NF-B/Rel-consensus sequence 5Ј-CCTTGAAGGGATTTCCCTCC-3Ј. The mutated (scrambled) form 5Ј-CCTTGTACCATTGTTAGCC-3Ј was used as a control (41) . The 1 M oligodeoxynucleotide was mixed with 5 g/ml of TransFast TM (Promega) for 15 min at room temperature, then the mixture was added to MCF-7 cells in serum-free medium. After 3 h of incubation, the cells were treated with HRG-␤1 for further appropriate times.
Electrophoretic Mobility Shift Assay-Confluent MCF-7 cells cultures were serum-starved overnight followed by stimulation with or without HRG-␤1 (50 ng/ml) for various time points. Nuclear extracts were prepared by using a nonionic detergent method as described previously (42) . In brief, nuclear extracts were prepared from breast cancer cells in extraction buffer (420 mM KCl, 20 mM HEPES (pH 7.9), 1.5 mM MgCl 2 , 0.2 mM EDTA, and 20% glycerol) plus protease inhibitors (0.5 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, and 10 g/ml leupeptin). After centrifugation at 14,000 rpm in a microcentri-fuge for 1 min, the supernatant was cytosol protein extracted and then placed into extraction buffer (the same concentration of the other reagents as in the extraction buffer except 500 mM KCl and 10% glycerol). After centrifugation at 14,000 rpm for 5 min, the supernatant fraction was harvested as the nuclear protein extract and stored at Ϫ70°C. Detection of NF-B was performed with a [␣- 32 P]dCTP-labeled oligo probe containing the NF-B recognition site. The probe was synthesized to span the region of the human VEGF-C promoter comprised between the ϩ395 and ϩ416: 5Ј-GGGGCCCAGGGGGGGTCGCCGGGAGG-GGGG-3Ј (random sequences added to the wild type sequence are shown in italics), in which the underlined region indicates the corebinding element. Protruding 5Ј ends were filled in with (exoϪ) Klenow fragment (from MBI Fermentas) and [␣-
32 P]dCTP. Nuclear protein (5 g) was added to 20 l of DNA-binding buffer (2 g of poly(dI-dC), 1 g of bovine serum albumin, 5 mM dithiothreitol, 20 mM HEPES (pH 8.4), 60 mM KCl, and 10% glycerol), which contained 5 ϫ 10 4 cpm [␣-32 P]-labeled oligonucleotide probe. The reaction mixture was incubation at room temperature for 20 min. For competition experiments, the cold oligonucleotide probe was added 15 min before addition of the probe. Super-shift assays were performed with 1 g of antibodies against p65 or p50 incubated 30 min at 4°C after addition of the probe. The reaction products were analyzed via 5% non-denaturing polyacrylamide gel electrophoresis using 12.5 mM Tris, 12.5 mM boric acid, and 0.25 mM EDTA (pH 8.3), for 4 -5 h at 280-300 V/10 -12 mA. The gels were dried and exposed to Amersham TM film (Amersham Biosciences) at Ϫ70°C using an intensifying screen.
Preparation of VEGF-C Promoter-Luciferase Fusion Constructs-The 2.5-kb VEGF-C promoter fragment was screened and obtained from a human placenta genomic library (in Lambda FIX II vector) using fulllength human VEGF-C cDNA, which was provided by Dr. R.-Y. Yu as a probe. The 2.5-kb fragment was restricted with XbaI (Ϫ1059) and RsrII (ϩ493), and the resulting 1552-bp fragment was cloned into the pGL3-basic vector to generate pGL3-1.5-kb VEGF-C. To delete the NF-B site (ϩ401 to ϩ410), we used PCR with following primers: forward (from Ϫ1040): 5Ј-AACTCGAGATTGGGAGTGAAAG; reverse (from ϩ345): 5Ј-CCAAGCTTGCTCCCGCCTTCCC. The amplified PCR products were restricted with XhoI and HindIII and cloned into the corresponding sites of pGL3-basic vector. The construct was designated as pGL3-1.4-kb/⌬NF-B VEGF-C promoter-reporter. To construct a plasmid containing the NF-B site mutations in 1.5-kb VEGF-C promoter, we used 1.5-kb VEGF-C promoter as a template and designed a mutated NF-B site (GGGGGTCGCCGG to GGGATTCTCCGG) by using the QuikChange Site-Directed Mutagenesis ® kit (Stratagene). The mutated construct was designated as pGL3-1.5-kb/mutNF-B VEGF-C promoter-reporter.
Promoter Activity Assay-For cell transfections, MCF-7 cells were seeded in 12-well plates in triplicate. When reaching about 70% confluence, the cells were transfected with pGL3-basic vector, pNF-B-Luc (BD Bioscience, Clontech), pGL3-1.5-kb VEGF-C, pGL3-1.4-kb/⌬NF-B, and pGL3-1.5-kb/mutNF-B VEGF-C using SuperFect ® Transfection Reagent (Qiagen, Valencia, CA). After transfection, the medium was replaced by fresh normal growth medium, and the cells were incubated for 24 h. After starvation in serum-free medium for 16 h, the cells were incubated in the presence or absence of HRG-␤1 (50 ng/ml) for another 1 or 6 h. The cells were harvested with passive buffer, and the luciferase activities were determined with the use of a Dual-Luciferase ® Reporter Assay system (Promega) according to protocols provided by the manufacturer. breast cancer MCF-7 cells treated with various cytokines and growth factors, whose altered levels have been shown to be associated with invasive or metastasis behavior in breast cancer cells. Fig. 1A shows that under the same circumstance, HRG-␤1 (50 ng/ml) was the most potent agent to induce VEGF-C, but not VEGF-D, mRNA expression in MCF-7 cells when compared with other agents. Among the agents tested, basic fibroblast growth factor and PMA also had significant inductive effects on the level of VEGF-C mRNA at the higher concentrations (Ͼ 50 ng/ml). As shown in Fig. 1B, upper panel , the VEGF-C mRNA level was elevated with a peak in the 3-9 h time period after 50 ng/ml HRG-␤1 treatment. Western blot analysis revealed that the 58-kDa VEGF-C precursor protein was significantly increased in the MCF-7 cells at 9 h and was sustained for up to 24 h post-HRG-␤1 treatment (Fig. 1B, lower  panel) . Fig. 1C reveals that the HRG-␤1-induced increase in VEGF-C mRNA (upper panel) and protein level (middle panel) appeared to be dosage-dependent. An initial increase of VEGF-C mRNA and protein was observed at a dose of 0.1 ng/ml HRG-␤1, and the maximal induction was found at a dose of 50 ng/ml. Fig. 1C , lower panel, shows that not only the 58-kDa VEGF-C precursor but also the 29/31-kDa mature VEGF-C protein could be increased by HRG-␤1 treatment. It is strongly suggested that VEGF-C protein induction by HRG-␤1 is functionally active in breast cancer cells. We next examined whether VEGF-C mRNA up-regulation by HRG-␤1 is due to increased transcription or increased RNA stability. To this end, we pretreated MCF-7 cells with 4 g/ml actinomycin D, a RNA synthesis inhibitor, or 30 g/ml cyclohexamide, a protein synthesis inhibitor, for 1 h before HRG-␤1 was added to the culture medium. Fig. 1D shows that actinomycin D completely abolished HRG-␤1-induced VEGF-C up-regulation, whereas cyclohexamide had no effect on VEGF-C induction by HRG-␤1. This finding suggests that HRG-␤1-induced VEGF-C up-regulation requires de novo RNA synthesis but not new protein synthesis.
RESULTS

HRG-␤1 Up-regulates VEGF-C in Human Breast
The effect of HRG-␤1 on VEGF-C mRNA expression in different breast cancer cell lines was further investigated. As shown in Fig. 2A , HRG-␤1 had a broad capacity to induce a VEGF-C mRNA increase (around 3-4-fold) in various human breast cancer cell lines, including SKBr3, T47D, and MCF-7. In support of a previous study (33) , we found that VEGF-A mRNA was also markedly elevated in breast cancer cell lines treated with HRG-␤1. Interestingly, among these cell lines, HBL-100 cells had a more abundant HRG-␤1 level and displayed higher levels of VEGF-C and -A mRNA, suggesting that endogenous HRG-␤1 is capable of inducing the VEGF-C mRNA expression. As previously described (26), HRG-␤1 preferentially binds to HER3 and HER4 receptors and then transactivates HER2 by forming a HER3/HER2 or HER4/HER2 heterodimer, which in turn elicits the signaling pathways for certain malignant properties. Here we asked whether the HER2 receptor is required for HRG-␤1-induced VEGF-C expression. Fig. 2B , left panel, shows that HER2-overexpressed MCF-7 cells displayed much more abundant levels of VEGF-C mRNA and protein as compared with the vector control cells. In addition, HRG-␤1-induced up-regulation of the VEGF-C mRNA or protein was completely blocked by treatment with Herceptin (an antibody against HER2 function) or PD153035 (an inhibitor of HER2 kinase) (Fig. 2B, right panel) . This evidence strongly suggests that the activity of the HER2 receptor is critical for HRG-␤1-mediated VEGF-C gene expression. To demonstrate the relationship between HER2 and VEGF-C in breast carcinoma, eight breast tumor RNA samples were detected with HER2 and VEGF-C mRNAs by using RT-PCR. Fig. 2C , upper panel, reveals that in HER2/neu overexpressing tumors, the VEGF-C is also overexpressed. Because human tumors are quite hetergeneous, we obtained mammary tumors from HER2/neu transgenic mice and isolated RNA for examining VEGF-C mRNA by using real-time RT-PCR. As expected, we found that the level of VEGF-C mRNA is significantly elevated in HER2-positive tumors compared with normal tissues (Fig. 2C, lower panel) . This result suggests that HER2/neu overexpression correlates with increased expression of VEGF-C in human breast cancers. (43, 44) . A putative NF-B-binding site was found to be located within the VEGF-C gene promoter region. This site may be implicated in the induction of VEGF-C mRNA by interleukin-1␤ and tumor
Activation of NF-B Is Required for VEGF-C ExpressionTranscription factor NF-B is one of the important factors activated by HRG-␤1 in human breast cancer cells
FIG. 2. HRG-␤1 treatment and HER2 overexpression up-regulate VEGF-C mRNA or protein expression in human breast cancer cell lines.
A, up-regulation of VEGF-C in multiple breast cancer cell lines treated with 100 ng/ml HRG-␤1 for 6 h. B, left panel, HER2/ neu stable transfectants displayed much more abundant levels of VEGF-C mRNA and protein. B, right panel, MCF-7 cells were pretreated with Herceptin (500 ng/ml) and PD153035 (2.7 M) for 1 h then treated with HRG-␤1 (50 ng/ml) for 6 or 9 h. VEGF-C mRNA or protein were detected by using RT-PCR and Western blotting in MCF-7 cells. C, upper panel, RT-PCR analysis of the expression of HER2 and VEGF-C mRNAs in human breast cancers. C, lower panel, real-time RT-PCR for examining VEGF-C mRNA in HER2/neu overexpressed mammary tumors (2 tumors) and normal tissue. The amount of VEGF-C mRNA in each sample was normalized against the amount of GAPDH mRNA in the same sample and subsequently expressed as the mRNA copy number of VEGF-C per 1000 copies of GAPDH mRNA. The data were the average of three independent experiments. Bar, standard error. necrosis factor-␣ (45, 46) . We thus tested if NF-B activation would be involved in HRG-␤1-induced VEGF-C mRNA expression. To this end, MCF-7 cells were exposed to 50 ng/ml HRG-␤1, nuclear extracts were prepared, and NF-B protein translocation as well as NF-B-binding activities were assessed respectively, by Western blotting and EMSA using an oligonucleotide corresponding to the putative NF-B-binding site within the VEGF-C promoter. As shown in Fig. 3A , the p65 and p50 NF-B subunits appeared in nuclear fractions at 30 -120 min after HRG-␤1 treatment. The nuclear proliferating cell nuclear antigen protein level is an internal control to ensure equal amounts of total nuclear protein. Consistently, the DNAbinding activity of NF-B increased significantly at 30 -120 min (Fig. 3B, upper panel, lanes 2-4) after HRG-␤1 treatment, and the induction of DNA-binding activity was completely attenuated by specifically competing with the non-radiolabeled probe (Fig. 3B, upper panel, lanes 5 and 6) . To quantify the NF-B activity, we transiently transfected a NF-B luciferase reporter into MCF-7 cells. The data of luciferase activity (Fig.  3B, lower panel) was correlated with the DNA-binding activity of NF-B in gel shift assay. Super-shift assays were done to confirm the presence of p50 and p65 binding to the NF-Bbinding site, showing that the specific protein-DNA-binding activity was super-shifted by the addition of anti-p65 or antip50 antibodies (data not shown). We next employed a NF-B decoy oligonucleotide, which sequenced as transcription factor decoys to inhibit NF-B binding to the native DNA sites, to specifically block HRG-␤1-induced activation of the NF-B pathway. Fig. 3C reveals that the NF-B decoy effectively blocked p65 subunit nuclear translocation (upper panel) as well as abolished the DNA-binding activity of NF-B (lower panel) induced by HRG-␤1. In contrast, the scrambled NF-B oligonucleotide had no effect on the nuclear translocation and DNAbinding activity of NF-B by HRG-␤1 treatment (Fig. 3C) . As shown in Fig. 3D , treatment with decoy NF-B completely inhibited HRG-␤1-mediated VEGF-C mRNA up-regulation, suggesting that NF-B activation is important for VEGF-C gene up-regulation by HRG-␤1. To identify whether the NF-B site is actually involved in transcriptional regulation of VEGF-C by HRG-␤1, we transiently transfected the 1.5-kb-VEGF-C promoter-reporter containing NF-B site, a NF-Bdeleted promoter plasmid, 1.4-kb/⌬NF-B VEGF-C, and a NF-B site mutated promoter plasmid, 1.5-kb/mutNF-B VEGF-C (see "Experimental Procedures") into MCF-7 cells and then examined their luciferase activities after HRG-␤1 treatment. Fig. 3E shows a 4.2-fold induction of a 1.5-kb VEGF-C promoter activity by treatment with 50 ng/ml HRG-␤1. However, HRG-␤1 had no effect on the luciferase activity of control pGL3-basic vector. When the NF-B-deleted and -mutated promoter-reporter, pGL3-1.4-kb/⌬NF-B VEGF-C and pGL3-1.5-kb/mutNF-B VEGF-C, were transfected into MCF-7 cells, their luciferase activities were decreased around 60% in response to HRG-␤1 when compared with pGL3-1.5-kb VEGF-C. These experiments demonstrate that the NF-B site is indeed important for HRG-␤1-mediated VEGF-C gene up-regulation.
The NF-B activation is intimately associated with the IB␣ phosphorylation and degradation. We thus tested whether HRG-␤1 could induce endogenous IB␣ phosphorylation and degradation. Western blot analysis shows that an evident IB␣ protein phosphorylation and a subsequent degradation occurred in the MCF-7 cells after HRG-␤1 treatment (Fig. 4A) . A DN-IB␣ vector, which is resistant to phosphorylation and degradation, was transfected and overexpressed in the MCF-7 cells. Overexpression of DN-IB␣ significantly repressed the NF-B-DNA-binding activity (Fig. 4B ) and NF-B nuclear translocation in MCF-7 cells after exposure to HRG-␤1 (data not shown). Under the same experimental conditions, we further examined whether DN-IB expression would modulate the HRG-␤1-induced VEGF-C gene expression. The data shown in Fig. 4C reveals that the HRG-␤1-mediated increase in VEGF-C mRNA (upper panel) and protein (lower panel) was strongly abolished in DN-IB␣ overexpressed cells but not in the control vector-transfected cells. These results suggest that IB␣ degradation and subsequent NF-B activation were required for VEGF-C gene expression induced by HRG-␤1.
p38 MAPK Is Involved in HRG-␤1-induced VEGF-C Gene Up-regulation-Many of the kinase signaling pathways have been shown to be activated and involved in HRG-␤1-induced diversified cellular functions (44, 47) . Therefore, we examined which of the kinase signaling pathways is/are required for HRG-␤1-induced up-regulation of the VEGF-C gene. To address this issue, MCF-7 cells were pre-treated with SB203580 (p38 MAPK inhibitor), PD98059 (MEK inhibitor), or LY294002 (PI3K inhibitor) for 1 h and followed by treatment with HRG-␤1 for 6 or 9 h, and total RNA and protein were used to determine VEGF-C expression. Fig. 5A reveals that 20 M of SB203580 completely reduced the increased level of VEGF-C mRNA (upper panel) and protein (lower panel) induced by HRG-␤1, whereas two other kinase inhibitors, PD98059 and LY294002, had no effect on the up-regulation of VEGF-C. As shown in Fig. 5B , HRG-␤1 indeed activated these three kinase pathways, p38 MAPK, ERK1/2, and PI3K, in MCF-7 cells as evidenced by the elevation of their phosphorylated form using their specific antibodies. Our data also demonstrated that these three signaling pathways were effectively blocked in MCF-7 cells when treatment with pharmacological inhibitors at the dose indicated (Fig. 5B) . It is suggested that those pharmacological inhibitors were functionally active in inhibiting the specific signaling pathways. Because SB203580 was demonstrated to significantly abolish VEGF-C gene up-regulation by HRG-␤1, we thus used another approach to test the importance of p38 MAPK by establishing a MCF-7 cell line expressing dominant-negative p38 (p38AF) and examined the expression level of VEGF-C mRNA and protein. Fig. 5C , upper panel, we demonstrated that HRG-␤1-stimulation of the phosphorylation of p38 MAPK was totally reduced in p38AF expressed cells but not in the control vector expressed cells. Blocking the p38 MAPK pathway by p38AF also significantly diminished the HRG-␤1-induced up-regulation of VEGF-C mRNA (Fig. 5C, middle panel) and protein (Fig. 5C, lower  panel) . In brief, these results suggest the possible involvement of p38 MAPK, but not ERK1/2 or PI3K, in the regulation of VEGF-C gene expression in breast cancer cells induced by HRG-␤1. p38 MAPK has recently been shown to regulate NF-B activity in certain cell systems (48, 49) , and we therefore explored the possible link between p38 MAPK and NF-B in HRG-␤1-mediated VEGF-C gene expression. To this end, we determined the NF-B DNA-binding activity and NF-B transcriptional activity in cells treated with different pharmacological inhibitors. Fig. 6A shows that the HRG-␤1-stimulated increase in NF-B DNA-binding activity and NF-B reporter activity were nearly abolished by SB203580 but not affected by PD98059 and LY294002. Consistently, HRG-␤1 treatment neither induced the nuclear translocation of NF-B p65 (Fig. 6B, upper panel) nor elevated the NF-B DNA-binding activity (Fig. 6B , lower panel) in p38AF-expressed cells as compared with control vector cells.
Our results suggest that blockage of p38 MAPK could prevent NF-B nuclear translocation, NF-B DNA-binding activity, and NF-B reporter activity by HRG-␤1. We further examined whether the level of phosphorylated IB␣ in cells expressing p38AF or treated with SB203580 would be changed. As expected, Western blot analysis showed that HRG-␤1-induced the elevation of phosphorylated IB␣ and its degradation was nearly completely abolished in cells treated with SB203580 (Fig. 6C, upper panel) or in cells expressing p38AF (Fig. 6C, lower panel) . Together, the data obtained here strongly suggests that p38 MAPK may act as an up-stream kinase to activate the NF-B-dependent up-regulation of VEGF-C in response to HRG-␤1.
DISCUSSION
In this study we demonstrated that activation of a novel signaling pathway from p38 MAPK to subsequent NF-B is a potential requirement for HRG-␤1-mediated up-regulation of the lymphangiogenic factor VEGF-C in human breast cancer cells. Although VEGF-C has been shown to be highly expressed in a vast array of malignant tissues, its up-regulation in cancer cells by which factor(s) is completely unknown. Few, if any, investigations have found that pro-inflammatory cytokines FIG. 3 . Activation of NF-B is required for VEGF-C expression. Nuclear extracts were prepared from serum-starved MCF-7 cells treated with 50 ng/ml HRG-␤1 for 0, 30, 60, or 120 min and 100 ng/ml PMA for 60 min as positive control. A, nuclear extracts were subjected to Western blot analysis by using indicated antibodies. B, upper panel, induction of NF-B DNA-binding activity by HRG-␤1 in MCF-7 cells. EMSA was performed as described under "Experimental Procedures." To test for specificity of binding, samples were incubated with 2 or 5ϫ excess unlabeled wild-type (URE). B, lower panel, NF-B transcriptional activity was measured by luciferase assay using an optimal NF-B-binding site in tandem followed by luciferase. The data were the representative of three independent experiments. C, MCF-7 breast carcinoma cultures were pretreated with phosphorothioate modified oligodeoxynucleotides (1 M). The sequence of NF-B oligodeoxynucleotides is shown under "Experimental Procedures." Western blot and EMSA performed on nuclear extracts after 60 min treated with 50 ng/ml HRG-␤1. D, MCF-7 cells were pretreated with 1 M decoy NF-B then treated with 50 ng/ml HRG-␤1 for 6 h. VEGF-C mRNA was detected by using RT-PCR. E, identification of NF-B in VEGF-C promoter. MCF-7 were transfected with 1.5-kb, 1.4-kb/⌬NF-B, and 1.5-kb/mutNF-B promoter-driven plasmids. After being incubated with 50 ng/ml HRG-␤1 for 6 h, the luciferase activity from transfectants were measured. The data were the average of three independent experiments. Bar, standard error.
such as interleukin-1␤ and tumor necrosis factor-␣ could strongly induce VEGF-C gene expression in human fibroblasts (46) . Here we show that neither IL-1␤ nor TNF-␣ were capable of up-regulating VEGF-C in human breast cancer cells (as can be seen in Fig. 1A) . Importantly, this is the first time it has been demonstrated that HRG-␤1 is a strong up-regulator of the VEGF-C gene in human breast cancer cells. In addition, our current data and that from others (15) suggest that the regulatory mechanism for the VEGF-C gene varies in different cellular contexts or in different pathological processes.
Accumulating evidence showed that overexpression of HRG-␤1 in human breast cancer cells resulted in the more aggressive phenotypes, i.e. enhancement in cell migration and invasion abilities (32, 50) . Many of the downstream effector genes, such as urokinase plasminogen activator (37, 51) , metalloproteinases (36), paxillin (38) , and autocrine motility factor (52), have been identified and may partially account for the role of HRG-␤1 in the progression of human breast cancer. How- . HRG-␤1 (50 ng/ml) was added to the media, cell lysates were collected after 9 h for Western blot analysis of VEGF-C expression, and total RNA was prepared from cells for RT-PCR analysis of VEGF-C mRNA after 6 h of HRG-␤1 treatment. B, to test the efficacy of inhibitors, MCF-7 cells were starved overnight, pretreated with the inhibitors at the concentrations as in Fig. 5A for 1 h, and stimulated by 50 ng/ml HRG-␤1 for 5 min. Cell lysates were prepared and subjected to Western blot analysis using antibodies against p-p38, p-ERK1/2, and p-AKT. C, MCF-7 cells were transfected with vector or p38AF and serum-starved for 24 h and treated with HRG-␤1 (50 ng/ml) for 6 or 9 h, analyzed on Western blotting and RT-PCR. ever, the detailed mechanism underlying how HRG-␤1 induces these downstream effector genes to coordinate with one another and arrange the aggressive phenotype is largely unknown. Here we provide evidence that shows the lymphangiogenic factor, VEGF-C, is induced in human breast cancer cells by HRG-␤1. The induction of VEGF-C does not require protein synthesis, suggesting that it may be mediated by activation of certain existing transcription factor(s) by post-translational modification or relocation. Consistent with this notion, we detected that the transcription factor NF-B is activated and critically required for HRG-␤1-induced VEGF-C up-regulation as evidenced by NF-B decoy treatment (Fig. 3C) and DN-IB␣ transfection (Fig. 4C) . Our data further points out that HRG-␤1-stimulation of NF-B DNA-binding activity is mainly through a mechanism involving phosphorylation-degradation of IB␣ and the subsequent translocation of NF-B into the nucleus. Supportively, the VEGF-C promoter-reporter assay clearly demonstrated that the putative NF-B site in the VEGF-C promoter region is critical for HRG-␤1-induced VEGF-C up-regulation (Fig. 3E) . Although the sequential activation of NF-B is commonly observed, this is the first time it has been shown that HRG-␤1 is capable of activating this mechanism in human breast cancer cells. NF-B activation plays a key role in drug resistance and metastasis in human breast cancer (53) (54) (55) . Here we report that the lymphangiogenic factor, VEGF-C, acts as one of the downstream effector genes of NF-B signaling. This provides a new aspect of NF-B in the pathogenesis of human breast cancer.
Many protein kinases including PI3K/Akt, ERK1/2, and p38 MAPK have been found to integrate into the activation process of NF-B in different cell systems in a distinct way (56 -58) . Our data demonstrates that in MCF-7 cells these three signaling pathways are all activated by HRG-␤1 (Fig. 5B) . Using a pharmacological and genetic inhibition approach, we found that only p38 MAPK signaling is specifically and dominantly involved in HRG-␤1-stimulated NF-B-dependent VEGF-C upregulation, although a possible cross-talk may occur between the p38 signaling and NF-B activation process. Currently, the mechanism for the interplay between these two pathways is not yet understood and may vary in different cell models. A recent study (57) revealed that the p38 pathway did not affect NF-B binding and transcriptional activity directly. Instead, it acts by enhancing the NF-B recruitment into a subset of gene promoters in response to inflammatory stimuli (57) . Distinct from that, in our cell model HRG-␤1-stimulated p38 signaling could promote IB␣ phosphorylation and degradation. Phosphorylation of IB␣ is carried out by the multisubunit IB kinase (IKK), which is in turn activated by the NF-B-inducing kinase (NIK) or by the mitogen-activated protein kinase (MEKK1) (59, 60) . How could p38 kinase signaling connect with the NF-B activation process? One possibility could be through phosphorylation of the IKK molecule. Several reports showed that not only NIK and MEKK1 but also Akt could 
HRG-␤1 Up-regulates VEGF-C in Breast Cancer Cells
phosphorylate IKK (61, 62) , suggesting that IKK could be as a key molecule to receive various kinase signaling and transmit into NF-B activation cascade. Supporting this hypothesis, we found that p38 kinase is closely associated with IKK in response to HRG-␤1 as demonstrated by co-immunoprecipitation using the anti-p38 antibody (data not shown). Alternatively, it is also possible that there may be a critically intermediate kinase connecting p38 signaling and IKK.
Ectopic overexpression of VEGF-C in different human breast cancer cells including MCF-7 and MDA-MB-435, all potently increased intratumoral lymphangiogenesis, resulting in significantly enhanced metastasis in the regional lymph nodes (5, 7, 63) . The 29/31-kDa mature form of VEGF-C, which specifically activates VEGFR-3, was obviously detected in both cell lines. Using a soluble form VEGFR-3 fusion protein inhibited the tumor growth and tumor-associated lymphangiogenesis by blocking the interaction between the mature form of VEGF-C and its receptor. Under the same MCF-7 cell system, we demonstrated that HRG-␤1-treated MCF-7 cells indeed produced a large amount of mature VEGF-C either in the total cell lysate (Fig. 1C) or in conditioned media (data not shown). This strongly suggests that the enhancement of lymphangiogenesis may partially account for HRG-␤1-mediating a more aggressive phenotype of human breast cancers. Our current data for cell lines, clinical specimens, and transgenic mice also show that HER2 receptor overexpression caused an increased expression of VEGF-C, thus suggesting that the level of HER2 receptor is another switch for promoting lymphangiogenesis in breast cancer. In agreement with our data, Yang et al. (64) have demonstrated that the expression of VEGF-A, -C, and -D was positively correlated with HER2/neu expression in human breast carcinomas (64) .
In summary, our findings identified for the first time that HRG-␤1 potently induces the up-regulation of VEGF-C mRNA and protein in human breast cancer MCF-7 cells through a novel signaling pathway from HER2 receptor, p38 MAPK, to the subsequent activation of NF-B cascade (Fig. 7) . Our study also provides a therapeutic rationale for the inhibition of breast tumor lymphangiogenesis using pharmacological inhibitors to block this signaling cascade or using Herceptin to inhibit HER2 activity.
